ST266 is a cell-free secretome, built around the molecules amniotic membrane progenitor cells secrete. Noveome is studying it in Phase I/II for necrotizing enterocolitis in premature infants. Xtalks interview → pharmaville.com/noveome-biot… #RareDisease #Biotech

Which pharma companies are shaping the next phase of biopharma? Fast Company’s 2026 list spotlights innovators across HIV prevention, non-opioid pain, RNAi, vaccines, cancer and women’s health. See Xtalks’ breakdown of the top 10 most innovative pharma companies of 2026: buff.ly/zj1ChpY #Pharma #Biopharma #LifeSciences #DrugDevelopment #PharmaInnovation

The New Endpoints Reshaping Oncology Trial Design Upcoming Webinar Hosted by Xtalks dlvr.it/TSzzC1

Clinical Trial Rescue: Fix Recruitment & Get Timelines Back on Track, Upcoming Webinar Hosted by Xtalks dlvr.it/TSzz44

Why do some drugs cost millions? Xtalks looks at the most expensive drugs in 2026, from Lenmeldy to Hemgenix, and explains how rare diseases, one-time gene therapies and complex manufacturing shape pricing. Read more: buff.ly/qOqsc6w #DrugPricing #GeneTherapy #RareDiseases #CellTherapy #PharmaNews

Chiesi’s Diego Ardigò shares what’s next in asthma and COPD R&D, and why the future of respiratory medicine depends on balancing innovation, patient experience and environmental sustainability. Listen now at buff.ly/eDfJIux 🎙️

Pharma and biotech M&A activity has been heating up this spring, with Eli Lilly especially active on the deal making front. With deals spanning genetic medicines, blood cancers, CAR-T, ADCs and sleep-wake disorders, take a look at the latest M&As in Xtalks’ deal watcher report. Read more: buff.ly/N3l5H5r #Pharma #Biotech #PharmaM&A #LifeSciences

Great to see this focus! But we need policies that keep pace if we want to KEEP our talent here 👍

From Biomarker to Market: Optimizing Access for Precision Therapies, Upcoming Webinar Hosted by Xtalks dlvr.it/TSz17v

Built to Scale: CRO Growth with the Right eClinical Partner, Upcoming Webinar Hosted by Xtalks dlvr.it/TSz0xZ

Build AI-Ready Pharma R&D to Accelerate Drug Development, Upcoming Webinar Hosted by Xtalks dlvr.it/TSz0hB

Which pharma companies are shaping the next phase of biopharma? Fast Company’s 2026 list spotlights innovators across HIV prevention, non-opioid pain, RNAi, vaccines, cancer and women’s health. See Xtalks’ breakdown of the top 10 most innovative pharma companies of 2026: buff.ly/zj1ChpY #Pharma #Biopharma #LifeSciences #DrugDevelopment #PharmaInnovation

Meet Xtalks Featured Community Member Dr. Laura Saltonstall, MD, MBA, Vice President, Medical Affairs, Immunology at Sobi. Combining clinical expertise with personal experience in rare disease, she is helping translate science into meaningful impact for patients and families. Read more: buff.ly/IuALdD9 #MedicalAffairs #RareDisease #Immunology #PatientCentricity #XtalksCommunity

$PLYX's CMO, Dr. Lisa Bollinger, & Director of Regulatory & Clinical Affairs, Dr. Minsu Kang, shared their views on how to ensure clinical trials find the right patients, measure meaningful outcomes & keep families in view at every step. Read more: bit.ly/4aaAMsC @Xtalks

$BRTX's CEO, Lance Alstodt, recently spoke with @Xtalks about the evolving landscape of regenerative medicine and the promise and challenges of stem cell-based therapies in treating chronic conditions like degenerative disc disease. Listen here: youtube.com/watch?v=n_Z89oBe…

For those with lysosomal storage disorders, what starts at the cellular level quickly becomes part of everyday life, including movement, communication, development, hospital visits and the constant logistics of care. In a conversation with @Xtalks, $PLYX’s, CMO and Director of Regulatory & Clinical Affairs opened up about what it takes to encourage rare disease programs into global clinical trials. Check out the coverage here: xtalks.com/what-it-takes-to-…

The science isn’t the bottleneck. Manufacturing is. Klotho's CEO, Dr. Joseph Sinkule, shares on @Xtalks Life Science Podcast why GMP-scale production and vector delivery are critical to unlocking the full potential of #genetherapies. Watch or listen: bit.ly/4kV2PR9

DiaMedica CEO, Rick Pauls, recently joined the @XTalks Life Science Podcast to discuss the significant unmet need in ischemic conditions caused by vascular dysfunction, such as #preeclampsia and #acuteischemicstroke, where effective treatment options remain limited. DiaMedica's mission is to transform care for these patients with DM199, a synthetic KLK1 protein designed to enhance blood flow and support tissue repair, potentially improving patient outcomes. Listen here: bit.ly/48Qw0jp $DMAC

NeuroOne Medical Technologies Corporation CEO Dave Rosa Featured on Xtalks Life Science Podcast Watch the Interview Here: ow.ly/b9ZK50YQHf8 $NMTC #NeuroOne #OneRF® @N1MTC ir.nmtc1.com

$PLYX CEO, Alex Yang, joined the @Xtalks Life Science Podcast to discuss our work accelerating treatment options for lysosomal storage disorders patients with urgent unmet need using our robust therapeutic portfolio and flexible clinical trial design. Listen here: xtalks.com/novel-therapeutic…